Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etentamig Compared With Standard Available Therapies in Relapsed or Refractory Multiple Myeloma
NCT06158841Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2024
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 25
01
Overview
Phase 3, randomised, open-label trial of etentamig in multiple myeloma (MM) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Progression Free Survival at 5 years and Objective Response Rate at 5 years. Started May 2024; status: active, not recruiting.
02
Drugs
etentamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06158841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06158841.